当前位置: X-MOL 学术Lancet Diabetes Endocrinol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Use of bone turnover markers in postmenopausal osteoporosis
The Lancet Diabetes & Endocrinology ( IF 44.5 ) Pub Date : 2017-07-06 , DOI: 10.1016/s2213-8587(17)30184-5
Richard Eastell , Pawel Szulc

Bone turnover comprises two processes: the removal of old bone (resorption) and the laying down of new bone (formation). N-terminal propeptide of type I procollagen (PINP) and C-telopeptide of type I collagen (CTX-I) are markers of bone formation and resorption, respectively, that are recommended for clinical use. Bone turnover markers can be measured on several occasions in one individual with good precision. However, these markers are subject to several sources of variability, including feeding (resorption decreases) and recent fracture (all markers increase for several months). Bone turnover markers are not used for diagnosis of osteoporosis and do not improve prediction of bone loss or fracture within an individual. In untreated women, very high bone turnover marker concentrations suggest secondary causes of high bone turnover (eg, bone metastases or multiple myeloma). In people with osteoporosis, bone turnover markers might be useful to assess the response to anabolic and antiresorptive therapies, to assess compliance to therapy, or to indicate possible secondary osteoporosis. Much remains to be learnt about how bone turnover markers can be used to monitor the effect of stopping bisphosphonate therapy (eg, to identify a threshold above which restarting therapy should be considered). More studies are needed to investigate the use of bone turnover markers for assessment of the bone safety of new medications.



中文翻译:

骨转换指标在绝经后骨质疏松症中的应用

骨转换包括两个过程:去除旧骨(吸收)和放下新骨(形成)。I型胶原蛋白的N端前肽(PINP)和I型胶原蛋白的C端肽(CTX-I)分别是骨形成和吸收的标志物,建议临床使用。可以在一个人中多次精确地测量骨转换标志物。但是,这些标志物易受多种变化的影响,包括进食(吸收降低)和最近的骨折(所有标志物持续数月都在增加)。骨转换标记物不用于诊断骨质疏松症,并且不能改善个体内骨质流失或骨折的预测。在未经治疗的妇女中,骨转换指标浓度很高会提示骨转换高的第二原因(例如 骨转移或多发性骨髓瘤)。在骨质疏松症患者中,骨转换标志物可能有助于评估对合成代谢和抗吸收疗法的反应,评估对治疗的依从性或表明可能的继发性骨质疏松症。关于如何将骨转换标记物用于监测停止双膦酸盐治疗的效果(例如,确定应考虑重新开始治疗的阈值),还有很多知识有待了解。需要更多的研究来研究使用骨转换标记物评估新药的骨安全性。关于如何将骨转换标记物用于监测停止双膦酸盐治疗的效果(例如,确定应考虑重新开始治疗的阈值),还有很多知识有待了解。需要更多的研究来研究使用骨转换标记物评估新药的骨安全性。关于如何将骨转换标记物用于监测停止双膦酸盐治疗的效果(例如,确定应考虑重新开始治疗的阈值),还有很多知识有待了解。需要更多的研究来研究使用骨转换标记物评估新药的骨安全性。

更新日期:2017-11-10
down
wechat
bug